Inpefa is labeled for use to reduce the risk ... t use X if you are allergic to X" that you hear all the time in drug ads). By comparison, Jardiance's indicated usage includes reducing the risk ...

Lexicon Pharmaceuticals recently gained FDA approval for its heart failure and type 2 diabetes drug, Inpefa, and is marketing the drug aggressively. Lexicon's financials show mixed results ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) plans to cut around 50% of its workforce, or more than 75 jobs, to prioritize commercialization of its drug sotagliflozin, also known as Inpefa and Zynquista.

Shares of Lexicon Pharmaceuticals LXRX jumped 12% on Tuesday after the company announced that its heart failure therapy Inpefa (sotagliflozin) will be placed as a preferred product on pharmacy ...

Experts say sotagliflozin, known commercially as Inpefa, is the first medication of its kind to deliver these unique cardiovascular benefits, potentially paving the way for broader use of the drug.

On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA® (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure ...

THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA ...

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin ...